pISSN 2636-0004
eISSN 2636-0012

Table. 2.

Adverse Events during Submucosal Tunnelling Endoscopic Resection (Selected Studies)

Study No. of patients/type of study Location of SET (n) Size, range (cm) Adverse events*
Ye et al (2014)31 85/prospective Esophagus = 60 1.9 (1.0–3.0) Total = 8 (9.4)
Cardia = 16 Pneumothorax = 6 (7.1)
Stomach = 9 Subcutaneous emphysema = 8 (9.4)
Pneumoperitoneum = 4 (4.7)
Chen et al (2016)5 290/retrospective Esophagus = 199 2.1 (1.0–7.0) Total = 68 (23.4)
Esophagogastric junction = 68 Subcutaneous emphysema = 61 (21)
Stomach = 23 Pneumothorax = 22 (7.6) (drainage = 3.1)
Pneumoperitoneum = 15 (5.2)
Mucosal injury = 3 (1) (clipping)
Major bleeding = 5 (1.7) (endoscopic coagulation)
Thoracic effusion = 49 (16.9) (drainage = 3.8)
Esophageal pleural fistula = 1 (0.3) (clipping)
Mao et al (2017)32 56/prospective Location of cardia tumor 1.8 (1.0–3.2) Total = 9 (15.3)
Above GE junction = 18 Subcutaneous emphysema = 9 (15.3)
Below GE junction = 38 Pneumoperitoneum = 9 (15.3)
Pneumothorax = 8 (14.3)
Pleural effusion = 5 (8.9)
Du et al (2019)33 165/retrospective Upper esophagus = 49 2 (0.5–8) Total = 35 (21)
Middle esophagus = 46 Esophageal tumor = 21 (19.8)
Cardia = 59 Cardia tumor = 14 (23.7)
Gas related complication = 16 (9.7)
Fever = 10 (6)
Mucosal injury = 10 (6)
Chest/abdominal pain = 4 (2.4)
Pleural effusion = 1 (0.6)
Perforation = 1 (0.6)

SET, subepithelial tumor; GE, gastroesophageal.

*Values are presented as number (%). More than one events patients.

Int J Gastrointest Interv 2020;9:86~97 https://doi.org/10.18528/ijgii200010
© Int J Gastrointest Interv